FY2028 Earnings Estimate for SRTS Issued By Roth Capital

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Research analysts at Roth Capital issued their FY2028 earnings per share (EPS) estimates for Sensus Healthcare in a note issued to investors on Thursday, February 6th. Roth Capital analyst J. Wittes anticipates that the company will post earnings of $0.30 per share for the year. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.71 per share. Roth Capital also issued estimates for Sensus Healthcare’s FY2029 earnings at $0.34 EPS.

Other analysts have also recently issued research reports about the company. Maxim Group upped their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Lake Street Capital initiated coverage on shares of Sensus Healthcare in a research report on Friday, January 31st. They set a “buy” rating and a $18.00 price target for the company. Finally, HC Wainwright raised their price objective on shares of Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Monday.

Sensus Healthcare Trading Up 3.9 %

Shares of SRTS opened at $6.07 on Monday. The firm has a fifty day simple moving average of $7.38 and a two-hundred day simple moving average of $6.89. The firm has a market cap of $99.48 million, a PE ratio of 15.18 and a beta of 1.24. Sensus Healthcare has a 1-year low of $2.91 and a 1-year high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SRTS. IFP Advisors Inc bought a new stake in Sensus Healthcare during the 4th quarter worth approximately $95,000. Sigma Planning Corp purchased a new stake in shares of Sensus Healthcare in the fourth quarter worth $215,000. Ritholtz Wealth Management raised its position in shares of Sensus Healthcare by 65.3% during the 4th quarter. Ritholtz Wealth Management now owns 51,261 shares of the company’s stock valued at $355,000 after purchasing an additional 20,256 shares during the period. Geode Capital Management LLC lifted its stake in shares of Sensus Healthcare by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after buying an additional 11,525 shares in the last quarter. Finally, XTX Topco Ltd boosted its holdings in Sensus Healthcare by 76.0% in the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock worth $183,000 after buying an additional 13,619 shares during the period. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.